AFFiRiS releases Phase II trial results of AD04 to treat Alzheimer’s disease
In the trial, AD04 showed clinical and biomarker effects consistent with disease modification in Alzheimer patients. Following treatment with AD04, effects consistent with disease modification were achieved for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.